openPR Logo
Press release

Spinal Cord Injury Pipeline Insights Report 2023 (Updated)

11-29-2023 11:12 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Spinal Cord Injury Pipeline

Spinal Cord Injury Pipeline

(Albany, United States) As per DelveInsight's assessment, globally, the Spinal Cord Injury Pipeline constitutes 35+ key companies continuously working towards developing 35+ Spinal Cord Injury Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Spinal Cord Injury Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Spinal Cord Injury NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Spinal Cord Injury Pipeline treatment landscape of the report, click here @ Spinal Cord Injury Pipeline Outlook- https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Spinal Cord Injury Pipeline Report
• DelveInsight's Spinal Cord Injury Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline treatment therapies.
• The leading companies working in the Spinal Cord Injury Market include Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
• Promising Spinal Cord Injury Pipeline Therapies in the various stages of development include KAI-1678, Tadalafil, FAB117-HC, NVG-291, MT-3921, ALMB-0166, NeuroAiD, KP-100IT, Elezanumab, and others.
• On March 2023, Neuroplast announced a study of phase 1 clinical trials for Neuro-Cells. This phase I clinical study is an open clinical trial to investigate the safety of the intrathecal application of Neuro-Cells in the treatment of end stage (chronic), traumatic complete (AIS grade A) and incomplete (AIS grade B/C) SCI patients. To that purpose, after inclusion in this study >1 year and less than 5 years after their SCI-event, 10 patients will be included.
• On August 2023, NervGen Pharma announced a study of phase 1 & 2 clinical trials for NVG-291. To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments.

Spinal Cord Injury Overview
Spinal Cord Injury (SCI) is a condition in which damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina) occurs. Spinal Cord Injury can be traumatic or non-traumatic.

For further information, refer to the detailed Spinal Cord Injury Unmet Needs, click here for Spinal Cord Injury Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Emerging Drugs Profile
• ES 135: Eusol Biotech
• MT-3921: Mitsubishi Tanabe Pharma Corporation

Spinal Cord Injury Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. Phase III include, Eusol Biotech.

Request a sample and discover the recent advances in Spinal Cord Injury Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Spinal Cord Injury Segmentation- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Drugs and Companies
• KAI-1678: KAI Pharmaceuticals
• Tadalafil: Eli Lilly and Company
• FAB117-HC: Ferrer International S.A.
• NVG-291: NervGen Pharma

Spinal Cord Injury Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Spinal Cord Injury Therapeutics Market include-
Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.

Dive deep into rich insights for drugs for the Spinal Cord Injury Pipeline, Click here @ Spinal Cord Injury Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Spinal Cord Injury Pipeline Report
• Coverage- Global
• Companies- Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
• Therapies- KAI-1678, Tadalafil, FAB117-HC, NVG-291, MT-3921, ALMB-0166, NeuroAiD, KP-100IT, Elezanumab, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Spinal Cord Injury Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Spinal Cord Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinal Cord Injury - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ES 135: Eusol Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MT-3921: Mitsubishi Tanabe Pharma Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NVG 291: NervGen Pharma
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. KAND-567: Kancera
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Spinal Cord Injury Key Companies
21. Spinal Cord Injury Key Products
22. Spinal Cord Injury- Unmet Needs
23. Spinal Cord Injury- Market Drivers and Barriers
24. Spinal Cord Injury- Future Perspectives and Conclusion
25. Spinal Cord Injury Analyst Views
26. Appendix

Important Published Links

https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spinal Cord Injury Pipeline Insights Report 2023 (Updated) here

News-ID: 3308484 • Views:

More Releases from DelveInsight Business Research LLP

Fragile X Syndrome (FXS) Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Alcobra, Actinogen, Autifony, Healx, Roche, Lysogene, Marinus Pharmaceuticals, Neuren Pharma, NovaMentis, Novartis, Prilenia
Fragile X Syndrome (FXS) Pipeline Assessment Covering Clinical Trials, Emerging …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Fragile X Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Fragile X Syndrome (FXS) Pipeline
Acute Kidney Injury Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AM-Pharma, Alexion, Alloksys, Aptabio Therapeutics, ArchBiopartners, Novartis, Ocelot Bio, River2Renal, Sentien
Acute Kidney Injury Pipeline Assessment Covering Clinical Trials, Emerging Thera …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Acute Kidney Injury therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Acute Kidney Injury Pipeline Insight"
Retinitis Pigmentosa Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MeiraGTx, Aldeyra, SparingVision, ProQR Therapeutics, RetroSense, Endogena, Nacuity Pharmaceuticals, jCyte, Ocugen, Neurotech
Retinitis Pigmentosa Pipeline Assessment Covering Clinical Trials, Emerging Ther …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Retinitis Pigmentosa Pipeline Insight" report by
Schizophrenia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Avanir, Boehringer Ingelheim, Cyclerion, Heptares, Medicell, Merck, Otsuka, Recognify, PsychoGenics, SyneuRx, Takeda, Valentech, Vigonvita
Schizophrenia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Schizophrenia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Schizophrenia Pipeline Insight" report by DelveInsight provides

All 5 Releases


More Releases for Spinal

Spinal Non-Fusion
Spinal implants are devices used for the treatment of spinal disorders such as disproportion and instability of spine. Spine surgical devices are broadly classified into fusion and non-fusion devices. Fusion devices heals by providing immediate and rigid immobilization, and non-fusion devices treats by replacing pro-inflammatory tissues, restoring spinal alignment, and decompressing neural elements while preserving functional movements rather than obliterating it. The advantages such as prolonged recuperation time, bone graft
Different Approaches to Spinal Fusion Market And Control Spinal Deformity Develo …
Spinal fusion is surgery to permanently join together two or more bones in the spine so there is no movement between them. For patients who require spinal fusion surgery to treat lumbar degenerative disc disease (DDD), spinal fusion device is a treatment option. Spinal fusion has been used for many years to treat many painful conditions in the lumbar (lower) spine. Over the past decade, there has been dramatic improvement in
Spinal Cord Compression-Spinal Stenosis Market Progresses for Huge Profits by 20 …
The Global Spinal Cord Compression-Spinal Stenosis Market is expected to reach $ 8.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 11.5 % during 2017-2023. Spinal stenosis is the abnormal narrowing of spinal canal causing it to restrict, which may result in a neurological deficit due to interference with neurological fibres. The associated symptoms include pain, numbness, loss of motor control etc.
Spinal Cord Compression-Spinal Stenosis Market Report: Industry Manufacturers An …
Marketresearchfuture.com includes Global Spinal Cord Compression-Spinal Stenosis Market by indications, by diagnosis, by end users - Global Forecast till 2023 is new report. Spinal cord compression is the second most frequent neurologic complication of cancer. Only in the United States, each year nearly 20,000 people with cancer develop spinal cord compression; this affected population represents 5% to 10% of the general cancer population. Request Sample copy of Spinal cord compression-spinal stenosis
Spinal Trauma Devices Market: Spinal Trauma Devices Sales to Surge Rapidly in Re …
The global spinal trauma devices market is dynamic and highly competitive. Only a couple of companies account for a substantial share in the market, thus lending it an oligopolistic vendor landscape. The market is largely dominated by DePuy Synthes, Medtronic, NuVasive, Inc., Stryker Corporation, and Globus Medical, Inc. The cumulative share of these companies added up to 79.1% in 2014, says Transparency Market Research (TMR) in a new report. As
Spinal Implants and Spinal Devices Market Analysis, Development and Demand Forec …
The global spinal implants and spinal devices market is growing, due to increasing demand for minimally invasive surgeries, increasing number of hospitals and surgical centers, and commercial applications in areas, such as nucleus arthroplasty, stem cell technology and artificial disk replacement. The spinal fusion and fixation technology dominates the market and the non-fusion/ motion preservation technology segment is expected to grow with the fastest rate during the forecast period, due